CY1113602T1 - ANTI-HTNFSF13B COMPETITIVE ANTIBODIES - Google Patents

ANTI-HTNFSF13B COMPETITIVE ANTIBODIES

Info

Publication number
CY1113602T1
CY1113602T1 CY20121100901T CY121100901T CY1113602T1 CY 1113602 T1 CY1113602 T1 CY 1113602T1 CY 20121100901 T CY20121100901 T CY 20121100901T CY 121100901 T CY121100901 T CY 121100901T CY 1113602 T1 CY1113602 T1 CY 1113602T1
Authority
CY
Cyprus
Prior art keywords
htnfsf13b
tnfsf13b
antibodies
activity
sec
Prior art date
Application number
CY20121100901T
Other languages
Greek (el)
Inventor
Valentina Pavlovna Gelfanova
John Edward Hale
Kristine Kay Kikly
Derrick Ryan Witcher
Radhakrishnan Rathnachalam
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02756428A external-priority patent/EP1432735B1/en
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1113602T1 publication Critical patent/CY1113602T1/en

Links

Abstract

Φέρονται στο προσκήνιο μονοκλωνικά αντισώματα ανθρώπου τα οποία δεσμεύονται ειδικά σε πολυπεπτίδια TNFSF13b. Αυτά τα αντισώματα έχουν υψηλή συγγένεια για hTNFSF13b (π.χ. KD = 10-8 Μ ή μικρότερη), βραδεία ταχύτητα διάστασης από την ένωση τους με τα TNFSF13b (π.χ., Koff= 10-3 sec-1 ή μικρότερη) και εξουδετερώνουν τη δραστικότητα TNFSF13b in vitro και in vivo. Τα αντισώματα κατά την εφεύρεση είναι χρήσιμα σε μία υλοποίηση αναστολής της δραστικότητας των TNFSF13b σε άνθρωπο που πάσχει από διαταραχή στην οποία η δραστικότητα των hTNFSF13b είναι επιβλαβής. Στην εφεύρεση περικλείονται επίσης νουκλεϊκά οξέα που κωδικοποιούν τα αντισώματα κατά την παρούσα εφεύρεση, ως επίσης φορείς και ξενιστικά κύτταρα προς έκφραση αυτών.Human monoclonal antibodies that bind specifically to TNFSF13b polypeptides are brought to the forefront. These antibodies have a high affinity for hTNFSF13b (e.g. KD = 10-8 sec or less), slow dissociation rate from their association with TNFSF13b (e.g., Koff = 10-3 sec-1 or less) and neutralize TNFSF13b activity in vitro and in vivo. The antibodies according to the invention are useful in an embodiment of inhibiting TNFSF13b activity in a human suffering from a disorder in which the activity of hTNFSF13b is harmful. Also included in the invention are nucleic acids encoding the antibodies according to the present invention, as well as vectors and host cells for expression thereof.

CY20121100901T 2001-08-16 2012-09-28 ANTI-HTNFSF13B COMPETITIVE ANTIBODIES CY1113602T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31280801A 2001-08-16 2001-08-16
EP02756428A EP1432735B1 (en) 2001-08-16 2002-08-15 Antagonistic anti-htnfsf13b human antibodies

Publications (1)

Publication Number Publication Date
CY1113602T1 true CY1113602T1 (en) 2016-06-22

Family

ID=58448919

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100901T CY1113602T1 (en) 2001-08-16 2012-09-28 ANTI-HTNFSF13B COMPETITIVE ANTIBODIES
CY20151100041T CY1115966T1 (en) 2001-08-16 2015-01-16 ANTI-HTNFSF13B COMPETITIVE ANTIBODIES

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20151100041T CY1115966T1 (en) 2001-08-16 2015-01-16 ANTI-HTNFSF13B COMPETITIVE ANTIBODIES

Country Status (1)

Country Link
CY (2) CY1113602T1 (en)

Also Published As

Publication number Publication date
CY1115966T1 (en) 2017-01-25

Similar Documents

Publication Publication Date Title
ECSP044978A (en) HUMAN ANTIBODIES ANTAGONISTS AGAINST hTNFSF13b
CY1113326T1 (en) HUMAN ANTIBODIES THAT CONNECT HUMAN IL-12 AND ITS PRODUCTION METHODS
CY1118443T1 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES
CY1118037T1 (en) ANTIBODIES AGAINST AVETA AND THEIR USE
ATE444361T1 (en) IL-17 AND IL-17R HOMOLOGUE POLYPEPTIDES AND THERAPEUTIC USES
CY1111283T1 (en) Molecules with extended half-lives, compositions and their uses
CY1113089T1 (en) Human Monoclonal Antibodies to Specific Protective Membrane Antigen (PSMA)
EA200800953A1 (en) HUMAN MONOCLONAL ANTIBODIES TO CD70
EA200301158A1 (en) CRIPTO BLOCKING ANTIBODIES AND THEIR APPLICATIONS
CY1116167T1 (en) PHARMACEUTICAL COMPOSITIONS GUIDED ON ERB-B1
CY1110571T1 (en) OPTIONAL MEDICAL VASCULAR OPTIONS-2
HRP20090517T1 (en) Interleukin-10 antibodies
ATE437184T1 (en) VARIANTS OF THE FC REGION
AR033978A1 (en) ANTIBODY MOLECULA WITH SPECIFICITY FOR HUMAN ALPHA TUMOR NECROSIS FACTOR AND USES OF THE SAME
EA200400510A1 (en) AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2
DK2163562T3 (en) IL-1 BETA-BINDING ANTIBODIES AND FRAGMENTS THEREOF
NO20054836L (en) Nogo reseptorbindingsprotein
ATE504602T1 (en) BINDING PROTEINS SPECIFIC TO HUMAN MATRIPTASE
BRPI0411854A (en) protein vehicles for vaccines
CY1106433T1 (en) COCCUDIO VACCINE
ATE370970T1 (en) ANTAGONISTIC HUMAN ANTI-HFAS LIGAND ANTIBODIES AND FRAGMENTS THEREOF
EA200600042A1 (en) METHODS OF FORMATION OF DISULFIDIC LINKS AND GLYCOSYLATION OF PROTEINS AND REAGENTS USED IN THESE METHODS
EA200300246A1 (en) GENES AND PROTEINS ASSOCIATED WITH SCHIZOPHRENIA
DE69840326D1 (en) INCREASING IMMUNE RESPONSE USING TARGETED MOLECULES
CY1115966T1 (en) ANTI-HTNFSF13B COMPETITIVE ANTIBODIES